Randomized Trial Compares Vaginal Misoprostol and IV Oxytocin for Labor Induction Efficacy
Background
Labor induction is a common obstetric procedure, often necessary for maternal or fetal indications. Current standard-of-care methods include intravenous oxytocin and vaginal misoprostol, both recognized for their safety and efficacy in stimulating uterine contractions. However, despite their widespread use, a direct, randomized comparison of their relative efficacy, time to delivery, and cost-effectiveness specifically in multiparous women at term undergoing labor induction remains underexplored. Understanding these differences is crucial for optimizing clinical protocols and patient outcomes.
Study Design
This randomized clinical trial is enrolling 130 multiparous women at term requiring labor induction. Participants will be randomly assigned to receive either vaginal misoprostol (Cytotec) or intravenous oxytocin (Pitocin). The primary endpoints include comparing the efficacy of each method, measured by successful induction and time to delivery. Secondary outcomes will assess the cost-effectiveness of both interventions. This design aims to provide a direct comparison of these two established methods in a specific patient population.
Why It Matters
The findings from this randomized trial could significantly refine labor induction protocols for multiparous women. By directly comparing vaginal misoprostol and IV oxytocin on efficacy, time to delivery, and cost, clinicians may gain clear evidence to select the optimal agent. This could lead to faster, more efficient inductions, potentially reducing maternal and fetal complications, and lowering healthcare expenditures. Identifying a superior or more cost-effective method will directly inform clinical guidelines, impacting patient care globally.
misoprostol
oxytocin
labor induction
multiparous women
clinical trial
obstetrics